{@shortdesc}

{@title}
{@headline}
Slide: {@currentrow} of {ds_RowCount}  PreviousStopPlayNext

The Drug Safety Executive Council (DSEC) is a peer-to-peer membership of over 1,500 drug safety leaders with the common objective of advancing the development of better and safer medicines.  Learn More.

DSEC is driven by an esteemed Advisory Board of industry executives representing many of the largest and most prominent biopharmaceutical companies in the world.  Regular membership is complimentary and limited to current employees of companies developing small and large molecule pharmaceuticals.
Why Join DSEC?

Regular membership is complimentary
Engage in member-driven discussions, research, and presentations that will help you lead your organization to better decision making
Access live events, on-demand events and a network of peers
Network with other high-level executives at leading biopharmaceutical companies to drive change that will encourage business growth
Membership is limited to leaders representing companies who develop small and large molecule pharmaceuticals

 
 
Featured Events & Content

DSEC in the News!
There was a recent article entitled: DSEC Recruits Pharmas For Early Drug Safety Testing published in Bio-IT World. See full article by clicking on title.
Live Webinar: Using in vitro Methods to Predict in vivo Toxicity
Please click the title above for more details.
On-Demand Webinar: The Adoption Process of Novel Technologies in Preclinical R&D
This web conference and panel discussion was held on November 5. Please click the title above for more details.
DSEC Sponsored Workshop at Molecular Medicine Tri-Conference
Collaborating to Accelrate the Adoption of Novel Technologies in the Preclinical R&D Process - Tuesday, February 24, 2009. San Francisco, California. Special Discount for DSEC members.
Executive Summary: Confronting Major Safety Issues of the 21st Century
Executive Summary from the Inaugural DSEC Member Summit
DSEC Sponsored Safety Tracks at the World Pharmaceutical Congress
We are now accepting proposed presentations for two DSEC sponsored tracks at the World Pharmaceutical Congress.
Cardiovascular Safety - Member Poll
Please click above to take a brief five question poll on cardiovascular safety.
Discrimination of Autonomic State VS. Impaired Repolarization
Current online discussion for DSEC Members. Join the discussion. October 2008

On-Demand Web Sessions

The Adoption Process of Novel Technologies in Preclinical R&D
Held on November 5, 2008
The Truth Behind Drug Safety Decision Making
Held on May 1, 2008
Seizing the Opportunities for Government Partnerships to Improve Drug Safety
Featuring Dr. Janet Woodcock, Deputy Commissioner and Chief Medical Officer, FDA. Held July 26, 2007

Executive Summaries: Benchmarking Studies/Reports

Executive Summary: Confronting Major Safety Issues of the 21st Century
Executive Summary from the Inaugural DSEC Member Summit
The Emergence of High-Content Screening as a Tool for Safety Assessment
Drug safety challenges rank as the leading cause of attrition of compounds in clinical development